Study demonstrates feasibility of antegrade instillation of Jelmyto for UTUCFebruary 11th 2022
“While Jelmyto is approved for both retrograde and antegrade instillation, the instructions for administration address retrograde instillation, and this is the first time that data on antegrade instillation has been documented in a clinical setting for this chemoablative therapy,” said Katie Murray, DO.
Is cisplatin eligibility status a factor in the prevalence of patients with UTUC receiving adjuvant therapy?February 9th 2022
“There are a few different approaches in perioperative medical chemotherapy or immunotherapy treatment, and it's unclear as to how we should consider all these different approaches,” says Shawn Dason, MD, FRCSC.
Gender disparities found in bladder cancer trials and real-world systemic therapy useFebruary 8th 2022
“We have to be more mindful and thoughtful about the fact that certain populations are underrepresented in clinical trials, and that’s likely due to a number of factors,” said co-author Padraic O’Malley, MD, MSc, FRCSC.
Final report of the OLYMPUS Jelmyto trial: Takeaways for urologistsJanuary 24th 2022
“I think that these data firmly establish UGN-101, or Jelmyto, as a bona fide treatment option for kidney preservation for patients with low-grade, non-invasive urothelial cancer in the upper urinary tract,” says Seth P. Lerner, MD.
Dr. Lerner on the pivotal OLYMPUS trial of Jelmyto in UTUCJanuary 20th 2022
“Of the 42 patients who achieved a complete response, 41 of those were evaluable for duration of response, which was the focus of the manuscript that was just published last month,” says Seth P. Lerner, MD.
Dr. Bupathi discusses JAVELIN Bladder 100 trial of maintenance avelumabJanuary 13th 2022
In the study, adding maintenance avelumab to best supportive care (BSC) led to a 31% reduction in the risk of death versus BSC alone in patients with unresectable locally advanced or metastatic urothelial cancer.
Erdafitinib efficacy in bladder cancer sustained with long-term follow-upJanuary 12th 2022
Erdafitinib is approved by the FDA for the treatment of adult patients with FGFR3/FGFR2-positive locally advanced or metastatic bladder cancer that has progressed on platinum-containing chemotherapy.
The current state of organ-sparing radical cystectomy for womenJanuary 3rd 2022
As an advocate for patients, Svetlana Avulova, MD, stresses the importance of this population of women with bladder cancer and how their desire to preserve sexual function through organ-sparing treatment should be recognized and validated.
Enhancing the negative predictive value of cystoscopyDecember 21st 2021
At the 2021 Society of Urologic Oncology Annual Meeting, Alexander Kutikov, MD, FACS, gave a presentation on determining and helping improve the negative predictive value of cystoscopy in ruling out muscle invasive bladder cancer.
Dr. Venkat discusses radical nephroureterectomy vs segmental ureterectomy for patients with UTUCDecember 17th 2021
At the 2021 Society of Urologic Oncology Annual Meeting, a study was presented by Siv Venkat, MD, FRCSC, that evaluates the outcomes of the bladder-sparing method of segmental ureterectomy versus radical nephroureterectomy.